KENVUE INC. $16 is a hold. The company (New York symbol KVUE; Consumer sector; Shares outstanding: 1.9 billion; Market cap: $30.4 billion; Dividend yield: 5.1%; Takeover Target Rating: Highest; www.kenvue.com) makes a variety of over-the-counter drugs and health products, including Tylenol, Band-Aid and Listerine.


Under pressure from Starboard Value and other activists, Kenvue has accepted a takeover offer from Kimberly-Clark Corp. (New York symbol KMB), the maker of personal care and tissue products.

We continue to monitor the activities of activist investors, as they tend to target struggling firms, like Cracker Barrel and Fluor, that could boost value by selling assets or changing management. However, both of those targeted stocks have limited short-term prospects.

On June 22, 2017, Brookfield Asset Management Inc. (now Brookfield Corp.) set up its specialty insurance business as a separate company called Trisura. Investors received one Trisura share for every 170 Brookfield shares they held.


Since then, the stock has soared over almost 500%. That’s mainly because the company is a leader in its niche business. Despite that big gain, we feel Trisura can continue to move higher, particularly as it’s winding down some of its riskier policies in the U.S. That should spur its earnings growth.



The company’s relatively small size could also turn it into an attractive takeover target for a larger industry player.

WELL HEALTH TECHNOLOGIES CORP. $3.91 is a buy for aggressive investors. The company (Toronto symbol WELL; Manufacturing sector; Shares outstanding: 253.9 million; Market cap: $992.7 million; No dividend paid; Takeover Target Rating: Medium; www.well.company) owns and operates Canada’s largest network of clinics supporting primary care, specialized care and diagnostics services. In the U.S., WELL Health provides healthcare services targeting specialized markets such as gastrointestinal, women’s health, primary care, and mental disorders.


In the quarter ended September 30, 2025, revenue jumped 55.7%, to $364.6 million from $234.1 million a year earlier. That gain was due to acquisitions and a 97.1% jump in the number of patient visits in Canada. Earnings soared to $41.0 million, or $0.16 a share, from $4.1 million, or $0.02.

Medical device maker Becton Dickinson hit record highs in 2020 thanks to strong demand for its COVID-19 testing kits. However, the stock suffered as the pandemic eased.


In response, Becton began a multi-year plan to streamline its operations. That included the April 2022 spinoff of its Diabetes Care business as embecta (see page 90). Investors received one share of embecta for every five common shares of Becton they held.



In early 2025, Becton announced a second spinoff—its Biosciences and Diagnostic Solutions operations. However, it ultimately opted to merge that business with a rival firm. That transaction will let the company pay down its debt and return more capital to shareholders.